



2031250PC.ST25\_seq.txt  
SEQUENCE LISTING

<110> Karyon Oy Ab  
<120> Tumor targeting agents and uses thereof  
<130> 2031250PC  
<150> FI 20021762  
<151> 2002-10-03  
<160> 8  
<170> PatentIn version 3.2  
<210> 1  
<211> 5  
<212> PRT  
<213> Artificial  
<220>  
<223> Synthetic  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> cysteine bridge  
<400> 1  
Cys Ile Arg Glu Cys  
1 5  
  
<210> 2  
<211> 5  
<212> PRT  
<213> Artificial  
<220>  
<223> Synthetic  
<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> cynteine bridge  
<400> 2  
Cys Glu Arg Ile Cys  
1 5  
  
<210> 3  
<211> 5  
<212> PRT  
<213> Artificial

2031250PC.ST25\_seq.txt

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> lactam bridge  
  
<400> 3

Asp Ile Arg Glu Lys  
1 5

<210> 4  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<220>  
<221> MISC\_FEATURE  
<222> (1)..(5)  
<223> lactam bridge  
  
<400> 4

Asp Glu Arg Ile Lys  
1 5

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<400> 5

Ile Gln Leu Arg Asp  
1 5

<210> 6  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<400> 6

2031250PC.ST25\_seq.txt

Ile Gln Leu Arg Asp Trp Gly Phe Ile Leu  
1 5 10

<210> 7  
<211> 5  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<400> 7

Leu Arg Glu Leu Ser  
1 5

<210> 8  
<211> 10  
<212> PRT  
<213> Artificial

<220>  
<223> synthetic

<400> 8

Leu Arg Glu Leu Ser Met Gly Tyr Phe Lys  
1 5 10